BlackRock’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-698,770
| Closed | -$10.4M | – | 5850 |
|
|
2022
Q4 | $10.4M | Buy |
698,770
+182,024
| +35% | +$2.52M | ﹤0.01% | 3375 |
|
|
2022
Q3 | $4.25M | Sell |
516,746
-7,463
| -1% | -$57.3K | ﹤0.01% | 3820 |
|
|
2022
Q2 | $3.44M | Sell |
524,209
-128
| -0% | -$620 | ﹤0.01% | 3980 |
|
|
2022
Q1 | $2.93M | Sell |
524,337
-3,489
| -0.7% | -$14.4K | ﹤0.01% | 4228 |
|
|
2021
Q4 | $2.48M | Sell |
527,826
-4,779
| -0.9% | -$29.6K | ﹤0.01% | 4319 |
|
|
2021
Q3 | $3.29M | Buy |
532,605
+53,813
| +11% | +$322K | ﹤0.01% | 4113 |
|
|
2021
Q2 | $3.15M | Sell |
478,792
-1,126,368
| -70% | -$7.77M | ﹤0.01% | 4076 |
|
|
2021
Q1 | $11.8M | Buy |
1,605,160
+36,805
| +2% | +$318K | ﹤0.01% | 3475 |
|
|
2020
Q4 | $9.05M | Buy |
1,568,355
+11,334
| +0.7% | +$64.9K | ﹤0.01% | 3410 |
|
|
2020
Q3 | $9.25M | Buy |
1,557,021
+685,045
| +79% | +$3.39M | ﹤0.01% | 3263 |
|
|
2020
Q2 | $4.49M | Buy |
871,976
+638,886
| +274% | +$4.03M | ﹤0.01% | 3565 |
|
|
2020
Q1 | $843K | Buy |
233,090
+579
| +0.2% | +$2.87K | ﹤0.01% | 3933 |
|
|
2019
Q4 | $1.45M | Buy |
232,511
+32,496
| +16% | +$239K | ﹤0.01% | 3885 |
|
|
2019
Q3 | $1.69M | Buy |
200,015
+236
| +0.1% | +$1.76K | ﹤0.01% | 3814 |
|
|
2019
Q2 | $1.34M | Sell |
199,779
-520,102
| -72% | -$4.46M | ﹤0.01% | 3914 |
|
|
2019
Q1 | $5.9M | Sell |
719,881
-15,891
| -2% | -$164K | ﹤0.01% | 3350 |
|
|
2018
Q4 | $11.8M | Buy |
735,772
+23,683
| +3% | +$521K | ﹤0.01% | 2999 |
|
|
2018
Q3 | $23.6M | Buy |
712,089
+14,314
| +2% | +$368K | ﹤0.01% | 2782 |
|
|
2018
Q2 | $15.8M | Buy |
697,775
+510,128
| +272% | +$12.1M | ﹤0.01% | 2992 |
|
|
2018
Q1 | $5.44M | Sell |
187,647
-529
| -0.3% | -$15.5K | ﹤0.01% | 3394 |
|
|
2017
Q4 | $5.25M | Buy |
188,176
+165
| +0.1% | +$5.12K | ﹤0.01% | 3424 |
|
|
2017
Q3 | $6.86M | Buy |
188,011
+1,189
| +0.6% | +$36.8K | ﹤0.01% | 3366 |
|
|
2017
Q2 | $4.15M | Sell |
186,822
-11,167
| -6% | -$87.9K | ﹤0.01% | 3520 |
|
|
2017
Q1 | $1.17M | Buy |
197,989
+197,922
| +295,406% | +$1.43M | ﹤0.01% | 3787 |
|
|
2016
Q4 | $0 | Hold |
67
| – | – | ﹤0.01% | 3843 |
|
|
2016
Q3 | $1K | Hold |
67
| – | – | ﹤0.01% | 3672 |
|
|
2016
Q2 | $1K | Hold |
67
| – | – | ﹤0.01% | 3698 |
|
|
2016
Q1 | $1K | Hold |
67
| – | – | ﹤0.01% | 3599 |
|
|
2015
Q4 | $1K | Buy |
+67
| New | +$796 | ﹤0.01% | 3410 |
|
|
2013
Q4 | – | Sell |
-20
| Closed | – | – | 3150 |
|
|
2013
Q3 | $0 | Hold |
20
| – | – | ﹤0.01% | 3127 |
|
|
2013
Q2 | $0 | Buy |
+20
| New | +$855 | ﹤0.01% | 3121 |
|
BlackRock's AVEO Position: Q1 2023 in Review
BlackRock sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 698,770 shares — an estimated $10.4M sold.
BlackRock first reported a position in AVEO in Q2 2013 and held it in 31 quarters. The position peaked at $23.6M in Q3 2018. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- BlackRock reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- BlackRock sold 698,770 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $10.4M.
- BlackRock first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 31 quarters.
- BlackRock's AVEO Pharmaceuticals, Inc. position peaked at $23.6M in Q3 2018.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.